Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

NCT05416307 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Interventions

DRUG: ELA026

Sponsor

Electra Therapeutics Inc.